Estrella Immunopharma, Inc. SEC filings ESLAW
Estrella Immunopharma, Inc. has 258 filings in SEC EDGAR's recent list, going back to Feb 19, 2021. Its latest annual report, Form 10-K, was filed on Mar 18, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 29, 2026 (officer or director change, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 424B3 | Prospectus | Feb 13, 2026 | — |
| S-1/A | Amended registration statement | Jan 22, 2026 | — |
| S-1/A | Amended registration statement | Jan 16, 2026 | — |
| 424B5 | Prospectus supplement | Jan 6, 2026 | — |
| S-1 | Registration statement | Dec 22, 2025 | — |
| S-8 | Employee stock plan registration | Dec 23, 2024 | — |
| 424B3 | Prospectus | Dec 17, 2024 | — |
| S-3 | Shelf registration | Dec 12, 2024 | — |
| 424B3 | Prospectus | Dec 9, 2024 | — |
| 424B3 | Prospectus | Nov 27, 2024 | — |
| 424B3 | Prospectus | Nov 18, 2024 | — |
| 424B3 | Prospectus | Oct 2, 2024 | — |
| 424B3 | Prospectus | Aug 21, 2024 | — |
| 424B3 | Prospectus | Aug 6, 2024 | — |
| 424B3 | Prospectus | Jul 2, 2024 | — |
| 424B3 | Prospectus | May 15, 2024 | — |
| 424B3 | Prospectus | Mar 11, 2024 | — |
| 424B3 | Prospectus | Mar 7, 2024 | — |
| 424B3 | Prospectus | Feb 16, 2024 | — |
| 424B3 | Prospectus | Feb 12, 2024 | — |
| 424B3 | Prospectus | Dec 28, 2023 | — |
| S-1/A | Amended registration statement | Dec 18, 2023 | — |
| S-1/A | Amended registration statement | Nov 13, 2023 | — |
| S-1 | Registration statement | Oct 11, 2023 | — |
| 424B3 | Prospectus | Jul 11, 2023 | — |
| S-4/A | Amendment no. 7 to form s-4 | Jul 10, 2023 | — |
| S-4/A | Amendment no. 6 to form s-4 | Jul 7, 2023 | — |
| S-4/A | Form s-4/a | Jun 30, 2023 | — |
| S-4/A | Form s-4/a | Jun 16, 2023 | — |
| S-4/A | Form s-4/a | May 2, 2023 | — |
| S-4/A | Filing | Feb 3, 2023 | — |
| S-4/A | Form s-4/a | Dec 19, 2022 | — |
| S-4 | Registration for a merger or exchange | Oct 18, 2022 | — |
| 424B4 | Prospectus | Jul 19, 2021 | — |
| S-1/A | Amended registration statement | Jul 9, 2021 | — |
| S-1/A | Amended registration statement | Jul 1, 2021 | — |
| S-1/A | Amended registration statement | Jun 11, 2021 | — |
| S-1/A | Amended registration statement | May 28, 2021 | — |
| S-1/A | Amended registration statement | May 25, 2021 | — |
| S-1/A | Amended registration statement | May 18, 2021 | — |
| S-1/A | Amended registration statement | May 7, 2021 | — |
| S-1/A | Amended registration statement | Apr 12, 2021 | — |
| S-1/A | Amended registration statement | Mar 29, 2021 | — |
| S-1 | Registration statement | Feb 19, 2021 | — |
Showing 44 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- ESLA (Nasdaq), ESLAW (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Emeryville, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1844417
- Former names
- TradeUP Acquisition Corp. (until Sep 20, 2023)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.